**Name of Journal:** *World journal of Gastroenterology*

**Manuscript NO:** 54470

**Manuscript Type:** REVIEW

**Potential of the ellagic acid-derived gut microbiota metabolite –** **Urolithin A in gastrointestinal protection**

Kujawska M *et al*. UA in GI protection

Małgorzata Kujawska, Jadwiga Jodynis-Liebert

**Małgorzata Kujawska, Jadwiga Jodynis-Liebert,** Department of Toxicology, Poznan University of Medical Sciences, Poznan 60631, Poland

**Author contributions:** Kujawska M wrote the manuscript; Jodynis-Liebert J revised the manuscript.

**Supported by** the National Science Centre, No. 2017/26/D/NZ7/00748.

**Corresponding author: Małgorzata Kujawska**, **MSc, PhD, Adjunct Professor, Associate Professor,** Department of Toxicology, Poznan University of Medical Sciences, Dojazd 30, Poznan 60631, Poland. kujawska@ump.edu.pl

**Received:** January 31, 2020

**Revised:** May 19, 2020

**Accepted:** May 23, 2020

**Published online:**  June 21, 2020

**Abstract**

Urolithin A (UA) is a metabolic compound generated during the biotransformation of ellagitannins by the intestinal bacteria. The physiologically relevant micromolar concentrations of UA, achieved in the plasma and gastrointestinal tract (GI) after consumption of its dietary precursors, have been revealed to offer GIprotection. The health benefit has been demonstrated to be principally related to anticancer and anti-inflammatory effects. UA has been shown to possess the capability to regulate multiple tumor and inflammatory signaling pathways and to modulate enzyme activity, including those involved in carcinogen biotransformation and antioxidant defense. The purpose of this review is to gather evidence from both *in vitro* and *in vivo* studies showing the potential of UA in GI protection alongside suggested mechanisms by which UA can protect against cancer and inflammatory diseases of the digestive tract. The data presented herein, covering both studies on the pure compound and *in vivo* generated UA form its natural precursor, support the potential of this metabolite in treatment interventions against GI ailments.

**Key words:** Urolithin A; Colonic metabolite; Gut microbiota; Colorectal cancer; Inflammatory bowel diseases; Hepatocellular carcinoma; Pancreatic ductal adenocarcinoma; Barrett’s esophagus; Ellagitannins

**Citation:** Kujawska M, Jodynis-Liebert J. Potential of the ellagic acid-derived gut microbiota metabolite – Urolithin A in gastrointestinal protection. *World J Gastroenterol* 2020; 26(23): 3170-3181

**URL:** https://www.wjgnet.com/1007-9327/full/v26/i23/3170.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v26.i23.3170

**Core tip:** Urolithin A (UA) - an ellagitannin metabolite generated by the intestinal bacteria at physiologically relevant micromolar concentrations, offers gastrointestinal (GI) protection. The health benefit is principally related to anticancer and anti-inflammatory effects. UA can regulate multiple tumor and inflammatory signaling pathways and enzyme activities, including those involved in carcinogen biotransformation and antioxidant defense. The presented herein data support the potential of both pure compound and *in vivo* generated UA in treatment interventions against GI ailments.

**INTRODUCTION**

The human gastrointestinal tract (GI) is colonized by a large number of microbes, which is ten times higher than the total number of human cells[1]. The intestinal microbiota, being an integral part of the host system, has emerged as a key modulator of health and disease risk. Indeed, microbes that reside in the human gut form a co-metabolism structure with the host to participate in various metabolic processes, including biotransformation of food substances[2]. There is increasing evidence of the involvement of gut microbiota on the health-beneficial effects of food[3]. Given this, microbial metabolites have recently been profoundly studied in phytopharmacology as potential sources of novel therapeutics. It has been demonstrated that phytochemicals, which are poorly absorbed in the intestine, undergo microbiota mediated biotransformation there, such as ring cleavage, demethylation, dihydroxylation, deglycosylation, *etc*. The generated metabolites can be absorbed and distributed into various tissues, which often correlates with lowered disease risk[4]. Ellagitannins (ETs), a class of hydrolyzable tannins found mainly in pomegranate, berries and nuts, are hydrolyzed spontaneously into ellagic acid (EA) during digestion in the upper GI tract. EA can be transformed by the gut microbiota to urolithins D, C, A and B in the intestine and then transported into blood circulation through intestinal epithelial cells as their lipophilicity increases[5-7]. Absorbed urolithins, which reach micromolar concentrations in the bloodstream, undergo phase I and II metabolism including methylation, glucuronidation, and sulfation[8,9]. The presence of urolithins, including urolithins A, in peripheral plasma and their glucuronides and methyl glucuronides in bile after the administration of ETs to pigs, confirms a very active enterohepatic circulation[10]. A regular intake of ET-rich food has been reported to enable the achievement of physiologically relevant concentrations of urolithins and their phase II derivatives in plasma. However, it has been found that their concentration in plasma after consumption of dietary precursors varies considerably between individuals[8,9]. In addition, significant differences among subjects in the ability to produce the final urolithins and the health benefits associated with consumption of ET-containing food products have been reported due to the various compositions of their gut microbiota[11]. In respect to the microbial metabolism, individuals are stratified into three urolithin metabotypes: metabotype A – individuals producing only urolithin A (UA, 25%-80% of the volunteers), metabotype B, yielding isourolithin A and/or urolithin B in addition to UA (10%-50%), and metabotype 0, which is not able to produce any urolithin (5%-25%). Remarkably, metabotype B has been reported to be associated with gut microbial dysbiosis and colorectal cancer (CRC) in patients (reviewed in[12]). Three urolithin-producing bacteria from the human gut belonging to the *genus* *Gordonibacter* (*G.* *pamelaeae* and *G. urolithinfaciens*) and *Ellagibacter isourolithinifaciens* have been identified to correlate with metabotype A positively[13]. Recently, Gaya *et al*[14] have reported that also *Bifidobacterium pseudocatenulatum* strain can produce UA.

UA (3,8-dihydroxy-dibenzopyranone), including its glucuronide derivative, has been found to be the predominant isoform of urolithins found in the plasma and urine following the consumption of ETs (reviewed in[8]). It has been demonstrated that this metabolite is also accumulated in organs. The presence of UA in rodent colon, intestinal, prostate and even brain tissues has been reported, whereas UA glucuronide was primarily detected in liver and kidney tissues[7,15,16]. UA has been demonstrated both in *in vitro* and *in vivo* experiments to possess a broad spectrum of bioactivities, including antioxidative, anti-inflammatory, antiproliferative and apoptosis-inducing that might contribute to potential cancer chemoprotection (reviewed in[3]). Since bioavailability of urolithins and their anti-inflammatory, antioxidant and antiproliferative properties are higher relative to parent compounds, the biological activity of EA and ETs including their chemopreventive and chemotherapeutic effects, have been suggested to be mediated by these metabolites[9].

The purpose of this review is to gather evidence from *in vitro*, *in vivo* and clinical studies showing the potential of UA in GI protection alongside suggested mechanisms by which UA can protect against cancer and inflammatory diseases of the digestive tract.

**INTESTINE**

Given the location of UA generation, it can be expected that UA exerts its effects within the intestinal tract and intestinal walls. This may include inhibitory effects on CRC and suppressive effects on inflammatory bowel diseases (IBDs)[17]. Results of human and animal studies and an experiment performed in the combined SHIME/Caco-2 cell system have indicated that UA can occur along the GI tract, from the duodenum to the rectum, upon long-term ETs consumption due to enterohepatic circulation[10,18]. Moreover, free availability of UA in inflammatory microenvironmental sites due to tissue deconjugation, especially within the intestinal tract, demonstrated in a systemic inflammation rat model, supports its beneficial effects on IBDs or in colon cancers[19]. Based on these findings, it is likely that UA provides significant protection against common intestinal pathologies.

***CRC***

Numerous studies have given evidence of the beneficial effects of this metabolite against CRC, which is the third most commonly diagnosed malignancy and the second leading cause of cancer death worldwide[20]. Most of these reports documenting chemopreventive effects are based on *in vitro* studies. UA has been demonstrated to cause a dose-dependent[21-24], a time-dependent[25,26] and both a concentration- and time-dependent proliferation decrease of CRC cell lines[27,28]. Moreover, it has been revealed that a mixture containing mostly UA (85%) and its precursors - urolithin C and EA, at concentrations detected in colon tissues of individuals with metabotype A following the intake of ET-rich food, exerted inhibitory activity against colon cancer stem cells (CSCs), which are considered to be involved in the control of cancer metastasis and the acquisition of chemotherapy resistance[29]. The inhibition of cell proliferation was accompanied by cell cycle arrest in the G2/M and S stages[26-28], and in the G2/M phase[21-23] followed by induction of apoptosis[21-23,26]. Since the delay in the G2/M transition has been reported to be a hallmark of topoisomerase II inhibition[30], potent catalytic inhibition of this human enzyme by UA could be suggested. However, competition tests performed for submicromolar concentrations did not confirm this property of UA, which was inactive up to 5 μmol/L[31]. Several reports indicate that UA-induced apoptosis is associated with increased caspases activity[22,23]. More recent evidence[28] showing a dose-dependent anti-clonogenic effect of long-term exposure to UA in CRC cell lines, indicates that a decrease in the colony formation is exerted through the senescence induction *via* the p53/p21 pathway, rather than by cell cycle arrest or apoptosis, which required much higher concentrations[28]. These data are consistent with previous results[32], also suggesting that the antiproliferative effect of long-term exposure to UA in a colon cancer cell line was mediated through the p53/p21-dependent senescence-like growth arrest. This action was synergistic with the standard chemotherapeutic drug oxaliplatin[32]. González-Sarrías *et al*[33] have also demonstrated that UA at concentrations achievable in the human colorectum, can potentiate the anticancer effects of 5-fluorouracil (5-FU) on human colon cancer cells. Interestingly, unchanged tannins such as proanthocyanidins extracted from grape seeds, have also been demonstrated to exert anti-tumorigenic effects on colon cancer cells through inhibition of cellular proliferation[34,35], induction of apoptosis and cell cycle arrest, inhibition of the formation of spheroid derived stem-like colon cancer cells[35] as well as by enhancing the impact of 5-FU chemotherapy. However, the activity of PCs has been limited to the proximal jejunum, due to its degradation in the distal region of the small intestine[34]. It has now been suggested that the anticancer effects of UA may also result from autophagy induction since, at concentrations found in the intestine after dietary polyphenols’ consumption, it triggered autophagy, and as a result, inhibited CRC cell growth and metastasis[21]. Kojadinovic *et al*[36] have demonstrated that both long- and short-term exposure of colorectal adenocarcinoma Caco-2 cells to a mixture of UA and UB, at concentrations reached in the lumen of the gut, contributed to the reduction of oxidative stress, thus preventing the damage caused by reactive oxygen species. The colon cancer chemopreventive property of UA has been supported through the inhibition of CYP1 enzymes involved in the metabolic activation of dietary carcinogens[23,37]. On the other hand, González-Sarrías *et al*[25] have revealed the induction of *CYP1A1* gene expression and activity in the Caco-2 cells after exposure to UA, suggesting that this could reflect the mobilization of detoxification mechanisms. The *CYP1A1* induction was accompanied by increased mRNA expression of an enzyme catalyzing the glucuronidation reaction, which is generally considered to facilitate detoxification of potential colon carcinogens[25].

Although there are numerous *in vitro* studies supporting UA as a CRC chemopreventive agent, there is a lack of clinical evidence in this area. The only study by Nuñez-Sánchez *et al*[38] has revealed that the consumption of an ET-containing pomegranate extract counterbalanced the expression of several CRC-related genes in cancerous colon tissues; however, this effect was not associated with the UA level in these tissues.

Data on the chemopreventive activities of UA against CRC are presented in Table 1.

***IBDs***

Chronic inflammation is regarded to be involved in approximately 20% of all human cancers. The tight link between long-standing inflammation of the GI tract and carcinogenesis is most apparent in CRC. IBDs, and particularly ulcerative colitis, are thought to be at increased risk for CRC. It is supported by the results of epidemiological studies indicating that IBDs and CRC have a similar prevalence worldwide[39]. The anti-inflammatory effects of UA, which has been demonstrated in lipopolysaccharide (LPS)-induced inflammation in RAW 264.7 murine macrophages[40], may be especially relevant in the intestine, where it can reach considerable micromolar concentrations through a diet rich in ETs. Giménez-Bastida *et al*[41] have demonstrated that UA can contribute to the prevention of intestinal inflammations also in colon fibroblasts - cells playing a pivotal role in the inflammatory response sincethe increased permeability of the tight junctions then allows for direct contact of luminal content with the cells resident in the lamina propria. UA at a concentration that is achieved in the colon through the diet has been found to inhibit two critical processes of the intestinal inflammatory response: fibroblast migration and monocyte adhesion that was accompanied by the downregulated expression of their modulatory factors. The reduction of the colon fibroblast migration, mediated by UA, might protect against excessive fibrosis as mechanisms controlling wound healing become disordered in IBDs. Overall, UA contributed to the prevention against the detrimental effect of inflammation on the cells’ viability, which was slightly improved following exposure to the metabolite[41]. In a dextran sodium sulfate (DSS)-induced colitis rat model, pre- and co-treatment with UA attenuated the severity of colon injury as preserved mucosal architecture and a decreased epithelium loss have been observed, which was accompanied with improved hematological parameters. The effects were due to the attenuation of inflammatory signaling and the upregulation of the tumor suppressor genes[42]. Of note, procyanidins have been reported to decrease the severity of selected markers of DSS-induced colitis; however, only in the distal ileum and proximal colon. The declined bioactivity of procyanidins in the large bowel has been suggested to be due to their degradation by endogenous microflora[43]. In addition, UA has been shown to modulate the gut microbiota composition favorably in DSS-treated rats, and the authors of the experiment have suggested the prevention of dysbiosis as an additional protective mechanism of UA against intestinal inflammatory diseases[42]. The importance of functional dynamics of gut microbiota and their metabolites has recently become the object of studies, including those concerning intestine health[41,44,45]. The black raspberries diet is also a source of UA that has been demonstrated in mice to impact colon mucosal microbial composition with a robust effect in the luminal microflora[44]. In addition urolithins at concentrations achievable in the gut through the diet, including UA, have been suggested to exert inhibitory effects against intestinal pathogens[46]. Besides its anti-inflammatory activity, UA has been reported to improve gut health by enhancing barrier function[45]. This ETs-derived microbial metabolite has been demonstrated to enhance the expression of tight junction proteins such as claudins, Zona occluding-1, and occludin that are critical for epithelial cell barrier functions and to inhibit inflammation both in cell lines and in mice. These effects were a result of activating the phase I (AhR-Cyp1A1) and phase II (Nrf2-antioxidative pathways) metabolic pathways. In mice, oral treatment with UA significantly mitigated systemic inflammation and colitis supporting its important role in the regulation of barrier function[45]. Muku *et al*[47] have demonstrated that UA was able to attenuate chemically induced stimulation of CYP1A1 mRNA levels in Caco-2 cells, that was accompanied by inhibition of mRNA levels, both basal and cytokine-induced interleukin 6 and prostaglandin-endoperoxide synthase 2 in the human Caco-2 cell line. These effects, at least in part, were due to competitive binding with an aryl hydrocarbon receptor (AhR) since AhR knockdown by siRNA prevented the UA repression of the transcriptional activity regarding both CYP1A1 and inflammatory mediators. As an AhR antagonist, UA failed to induce AhR retention in the nucleus[47]. However, the authors have pointed towards the risks of uninterrupted excessive AhR activation caused by inflammatory signaling such as Toll-like receptor activation or cytokine release in the tumor microenvironment. Thus, antagonizing AhR by UA has been found to be beneficial to maintain balanced AhR activity for overall homeostasis and to prevent pathological conditions correlating with elevated AhR activity such as cancer[47]. Data on the anti-inflammatory activity of UA relevant to the intestine are presented in Table 2.

**LIVER**

According to the “World Cancer Report 2014”[48] published by the International Agency for Research on Cancer, liver cancer is the second largest cause of cancer death. The most common primary liver malignancy is hepatocellular carcinoma (HCC) which develops under the influence of chronic inflammation and oxidative stress[49]. Given the antioxidant, anti-inflammatory and antiproliferative activity of UA and its active enterohepatic circulation the chemopreventive potential of UA has also been studied with regard to hepatoprotection. In hepatic carcinoma cell lines, physiologically achievable micromolar concentrations of UA were sufficient to inhibit cell proliferation and induce cytotoxicity in a dose-dependent manner[50,51]. UA suppressed cell proliferation *via* caspase-3 dependent apoptosis[50,51] accompanied by down-regulation of the Bcl-2/Bax ratio. Moreover, Wang and co-workers[50] have shown that the antiproliferative effect of UA on HepG2 cells was due to the synergistic action of p38-MAPK activation and suppression of Wnt/β-catenin signaling. UA decreased protein expression of β-catenin and its downstream transcriptional factor c-Myc and Cyclin D1 thereby promoting p53 protein expression, which also resulted from a direct induction of p38-MAPK phosphorylation by UA. The capability of UA to affect Wnt signaling was demonstrated previously by Sharma *et al*[52], who observed this pathway inhibition with IC50 at 9 μg/mL (39 μmol/L) in a human 293T cell line. Given the fact that over 90% of colon cancers are believed to originate from activating mutations in the Wnt pathway[53], this finding by Wang *et al*[50] has proven the anticancer activity of UA against CRC. Additionally, since inflammatory response plays a crucial role at all stages of tumor development and HCC is an inflammation-driven disease with up to 90% of cases occurring on the background of chronic liver inflammation[54], the anti-inflammatory role of UA in HepG2 cells by blocking the NF-κB signaling pathway and therefore suppressing the release of inflammatory mediators supports its chemopreventive potential against HCC. Furthermore, the anti-inflammatory effect was accompanied by decreased intracellular ROS production and increased level of intracellular SOD and GPx activity[50]. The antioxidant property of UA has been supported by preventing in a dose-dependent manner the oxidative injury and cytotoxicity in cultured rat primary hepatocytes[55].

The leading risk factor for the development of HCC is the hepatitis B virus (HBV) infection. Accumulated evidence attributes the HBV-encoded x protein (HBx) as a multifunctional oncoprotein in the development of HCC. Previous studies have demonstrated that HBx can upregulate the proteins of the Lin28 family, known inhibitors of let-7a, classified as tumor-suppressor miRNAs[56,57]. Qiu *et al*[51] have revealed the capacity of UA to act against HBx relevant cell proliferation and invasion *via* regulation of the Lin28a/let-7a axis. In this study, UA also inhibited the expression of let-7a downstream targets, such as the high mobility group AT-hook 2 and K-ras, through regulation of the epithelial-to-mesenchymal transition occurring in the initiation of invasion and metastasis of tumor progression[51].

**OTHERS**

The capability of UA to target kinases downstream of KRAS, in particular, the PI3K/AKT/mTOR signaling pathways, has been demonstrated to be a promising therapeutic approach in pancreatic ductal adenocarcinoma (PDAC) treatment. UA treatment has inhibited human PDAC cell proliferation, migration, and enhanced apoptosis by blocking the phosphorylation of AKT and p70S6K *in vitro*. Interestingly, UA only slightly affects pAKT and p70S6K expression in normal epithelial cell lines, thereby suggesting its selective potential against cancer cells. The mechanism of the anticancer action of UA through the inhibition of AKT and p70S6K phosphorylation, reduction of proliferation, and enhancement of cellular apoptosis has been confirmed in both xenograft and transgenic mouse models of pancreatic cancer. Additionally, UA treatment has reprogrammed the tumor microenvironment, as evidenced by reduced levels of infiltrating immunosuppressive cell populations such as myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T-cells thus inhibiting tumor growth resulting in enhanced survival[58].

In Barrett’s esophagus (BE) patients, a 26-wk intervention with lyophilized black raspberries significantly increased GST-pi, a marker of detoxification, in BE epithelium, with over 50% of subjects responding favorably. The presence of UA-glucuronide and sulfate in the urine of the BE patients may support the involvement of UA in the observed beneficial effect on BE epithelium[59]. Data on the chemopreventive activities of UA against the above mentioned other cancers of the alimentary tract are presented in Table 3.

**CONCLUSION**

The above reviewed studies have revealed the multidirectional role of the gut bacterial metabolite UA in the regulation of multiple tumor and inflammatory signaling pathways and the modulation of enzyme activity, including those involved in carcinogen biotransformation and antioxidant defense. These mechanisms have been demonstrated to contribute to the alleviation of inflammation and counteraction of the growth of cancer cells in various structures and organs of GI. Based on the above, UA can be considered as a potential candidate to use as an anti-cancer or anti-inflammatory agent in treatment interventions related to GI ailments. Since UA concentrations in human serum and tissues depend on their gut microbial composition, the direct supplementation of UA would overcome the individual variation in microbiota among populations and offer health benefits.

**REFERENCES**

1 **Cani PD**. Human gut microbiome: hopes, threats and promises. *Gut* 2018; **67**: 1716-1725 [PMID: 29934437 DOI: 10.1136/gutjnl-2018-316723]

2 **Wang XQ,** Zhang AH, Miao JH, Sun H, Yan GL, Wu FF, Wang XJY. Gut microbiota as important modulator of metabolism in health and disease. *RSC Advances* 2018; **8**: 42380-42389 [DOI: 10.1039/C8RA08094A]

3 **Peirotén Á**, Bravo D, Landete JM. Bacterial metabolism as responsible of beneficial effects of phytoestrogens on human health. *Crit Rev Food Sci Nutr* 2019: 1-16 [PMID: 31161778 DOI: 10.1080/10408398.2019.1622505]

4 **Dey P**. Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions. *Pharmacol Res* 2019; **147**: 104367 [PMID: 31344423 DOI: 10.1016/j.phrs.2019.104367]

5 **Espín JC**, Larrosa M, García-Conesa MT, Tomás-Barberán F. Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. *Evid Based Complement Alternat Med* 2013; **2013**: 270418 [PMID: 23781257 DOI: 10.1155/2013/270418]

6 **Nuñez-Sánchez MA**, García-Villalba R, Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB, Sánchez-Álvarez C, García-Albert AM, Rodríguez-Gil FJ, Ruiz-Marín M, Pastor-Quirante FA, Martínez-Díaz F, Yáñez-Gascón MJ, González-Sarrías A, Tomás-Barberán FA, Espín JC. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. *Mol Nutr Food Res* 2014; **58**: 1199-1211 [PMID: 24532260 DOI: 10.1002/mnfr.201300931]

7 **García-Niño WR**, Zazueta C. Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. *Pharmacol Res* 2015; **97**: 84-103 [PMID: 25941011 DOI: 10.1016/j.phrs.2015.04.008]

8 **Tomás-Barberán FA**, González-Sarrías A, García-Villalba R, Núñez-Sánchez MA, Selma MV, García-Conesa MT, Espín JC. Urolithins, the rescue of "old" metabolites to understand a "new" concept: Metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. *Mol Nutr Food Res* 2017; **61** [PMID: 27158799 DOI: 10.1002/mnfr.201500901]

9 **Ismail T**, Calcabrini C, Diaz AR, Fimognari C, Turrini E, Catanzaro E, Akhtar S, Sestili P. Ellagitannins in Cancer Chemoprevention and Therapy. *Toxins (Basel)* 2016; **8** [PMID: 27187472 DOI: 10.3390/toxins8050151]

10 **Espín JC**, González-Barrio R, Cerdá B, López-Bote C, Rey AI, Tomás-Barberán FA. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. *J Agric Food Chem* 2007; **55**: 10476-10485 [PMID: 17990850 DOI: 10.1021/jf0723864]

11 **Selma MV**, Beltrán D, Luna MC, Romo-Vaquero M, García-Villalba R, Mira A, Espín JC, Tomás-Barberán FA. Isolation of Human Intestinal Bacteria Capable of Producing the Bioactive Metabolite Isourolithin A from Ellagic Acid. *Front Microbiol* 2017; **8**: 1521 [PMID: 28824607 DOI: 10.3389/fmicb.2017.01521]

12 **Gerhauser C**. Impact of dietary gut microbial metabolites on the epigenome. *Philos Trans R Soc Lond B Biol Sci* 2018; **373** [PMID: 29685968 DOI: 10.1098/rstb.2017.0359]

13 **García-Mantrana I**, Calatayud M, Romo-Vaquero M, Espín JC, Selma MV, Collado MC. Urolithin Metabotypes Can Determine the Modulation of Gut Microbiota in Healthy Individuals by Tracking Walnuts Consumption over Three Days. *Nutrients* 2019; **11** [PMID: 31623169 DOI: 10.3390/nu11102483]

14 **Gaya P,** Peirotén Á, Medina M, Álvarez I, Landete JM. Bifidobacterium pseudocatenulatum INIA P815: the first bacterium able to produce urolithins A and B from ellagic acid. *J Funct Foods* 2018; **45**: 95-99 [DOI: 10.1016/j.jff.2018.03.040]

15 **Seeram NP,** Zhang Y, Sartipipour M, Henning SM, Lee R-P, Harris DM, Moro A, Heber D. Pharmacokinetics and tissue disposition of urolithin A, an ellagitannin-derived metabolite, in mice. *FASEB Journal* 2007; **21**: A1081-A1081

16 **Kujawska M**, Jourdes M, Kurpik M, Szulc M, Szaefer H, Chmielarz P, Kreiner G, Krajka-Kuźniak V, Mikołajczak PŁ, Teissedre PL, Jodynis-Liebert J. Neuroprotective Effects of Pomegranate Juice against Parkinson's Disease and Presence of Ellagitannins-Derived Metabolite-Urolithin A-In the Brain. *Int J Mol Sci* 2019; **21** [PMID: 31892167 DOI: 10.3390/ijms21010202]

17 **Kawabata K**, Yoshioka Y, Terao J. Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols. *Molecules* 2019; **24** [PMID: 30669635 DOI: 10.3390/molecules24020370]

18 **García-Villalba R**, Vissenaekens H, Pitart J, Romo-Vaquero M, Espín JC, Grootaert C, Selma MV, Raes K, Smagghe G, Possemiers S, Van Camp J, Tomas-Barberan FA. Gastrointestinal Simulation Model TWIN-SHIME Shows Differences between Human Urolithin-Metabotypes in Gut Microbiota Composition, Pomegranate Polyphenol Metabolism, and Transport along the Intestinal Tract. *J Agric Food Chem* 2017; **65**: 5480-5493 [PMID: 28616977 DOI: 10.1021/acs.jafc.7b02049]

19 **Ávila-Gálvez MA**, Giménez-Bastida JA, González-Sarrías A, Espín JC. Tissue deconjugation of urolithin A glucuronide to free urolithin A in systemic inflammation. *Food Funct* 2019; **10**: 3135-3141 [PMID: 31041969 DOI: 10.1039/c9fo00298g]

20 **World Health Organization.** Colotectal cancer. Available from: URL: http://gco.iarc.fr/today/data/factsheets/cancers/10\_8\_9-Colorectum-fact-sheet.pdf

21 **Zhao W**, Shi F, Guo Z, Zhao J, Song X, Yang H. Metabolite of ellagitannins, urolithin A induces autophagy and inhibits metastasis in human sw620 colorectal cancer cells. *Mol Carcinog* 2018; **57**: 193-200 [PMID: 28976622 DOI: 10.1002/mc.22746]

22 **Cho H**, Jung H, Lee H, Yi HC, Kwak HK, Hwang KT. Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells. *Food Funct* 2015; **6**: 1675-1683 [PMID: 25906041 DOI: 10.1039/c5fo00274e]

23 **Kasimsetty SG**, Bialonska D, Reddy MK, Ma G, Khan SI, Ferreira D. Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins. *J Agric Food Chem* 2010; **58**: 2180-2187 [PMID: 20112993 DOI: 10.1021/jf903762h]

24 **Tortora K**, Femia AP, Romagnoli A, Sineo I, Khatib M, Mulinacci N, Giovannelli L, Caderni G. Pomegranate By-Products in Colorectal Cancer Chemoprevention: Effects in Apc-Mutated Pirc Rats and Mechanistic Studies In Vitro and Ex Vivo. *Mol Nutr Food Res* 2018; **62** [PMID: 28948694 DOI: 10.1002/mnfr.201700401]

25 **González-Sarrías A**, Azorín-Ortuño M, Yáñez-Gascón MJ, Tomás-Barberán FA, García-Conesa MT, Espín JC. Dissimilar in vitro and in vivo effects of ellagic acid and its microbiota-derived metabolites, urolithins, on the cytochrome P450 1A1. *J Agric Food Chem* 2009; **57**: 5623-5632 [PMID: 19469472 DOI: 10.1021/jf900725e]

26 **González-Sarrías A**, Núñez-Sánchez MÁ, Tomé-Carneiro J, Tomás-Barberán FA, García-Conesa MT, Espín JC. Comprehensive characterization of the effects of ellagic acid and urolithins on colorectal cancer and key-associated molecular hallmarks: MicroRNA cell specific induction of CDKN1A (p21) as a common mechanism involved. *Mol Nutr Food Res* 2016; **60**: 701-716 [PMID: 26634414 DOI: 10.1002/mnfr.201500780]

27 **González-Sarrías A**, Giménez-Bastida JA, Núñez-Sánchez MÁ, Larrosa M, García-Conesa MT, Tomás-Barberán FA, Espín JC. Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. *Eur J Nutr* 2014; **53**: 853-864 [PMID: 24077694 DOI: 10.1007/s00394-013-0589-4]

28 **Giménez-Bastida JA**, Ávila-Gálvez MÁ, Espín JC, González-Sarrías A. The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells. *Food Chem Toxicol* 2020; **139**: 111260 [PMID: 32179165 DOI: 10.1016/j.fct.2020.111260]

29 **Núñez-Sánchez MÁ**, Karmokar A, González-Sarrías A, García-Villalba R, Tomás-Barberán FA, García-Conesa MT, Brown K, Espín JC. In vivo relevant mixed urolithins and ellagic acid inhibit phenotypic and molecular colon cancer stem cell features: A new potentiality for ellagitannin metabolites against cancer. *Food Chem Toxicol* 2016; **92**: 8-16 [PMID: 26995228 DOI: 10.1016/j.fct.2016.03.011]

30 **Mikhailov A**, Shinohara M, Rieder CL. Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. *J Cell Biol* 2004; **166**: 517-526 [PMID: 15302851 DOI: 10.1083/jcb.200405167]

31 **Furlanetto V**, Zagotto G, Pasquale R, Moro S, Gatto B. Ellagic acid and polyhydroxylated urolithins are potent catalytic inhibitors of human topoisomerase II: an in vitro study. *J Agric Food Chem* 2012; **60**: 9162-9170 [PMID: 22924519 DOI: 10.1021/jf302600q]

32 **Norden E**, Heiss EH. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells. *Carcinogenesis* 2019; **40**: 93-101 [PMID: 30418550 DOI: 10.1093/carcin/bgy158]

33 **González-Sarrías A**, Tomé-Carneiro J, Bellesia A, Tomás-Barberán FA, Espín JC. The ellagic acid-derived gut microbiota metabolite, urolithin A, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. *Food Funct* 2015; **6**: 1460-1469 [PMID: 25857357 DOI: 10.1039/c5fo00120j]

34 **Cheah KY**, Howarth GS, Bastian SE. Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells. *PLoS One* 2014; **9**: e85184 [PMID: 24465501 DOI: 10.1371/journal.pone.0085184]

35 **Toden S**, Ravindranathan P, Gu J, Cardenas J, Yuchang M, Goel A. Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer. *Sci Rep* 2018; **8**: 3335 [PMID: 29463813 DOI: 10.1038/s41598-018-21478-8]

36 **Kojadinovic M**, Arsic A, Petovic-Oggiano G, Gavrovic-Jankulovic M, Glibetic M, Popovic M. Effect of urolithins on oxidative stress of colorectal adenocarcinomacells-Caco-2. *Int J Food Sci Nutr* 2017; **68**: 952-959 [PMID: 28535698 DOI: 10.1080/09637486.2017.1328665]

37 **González-Sarrías A**, Espín JC, Tomás-Barberán FA, García-Conesa MT. Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. *Mol Nutr Food Res* 2009; **53**: 686-698 [PMID: 19437480 DOI: 10.1002/mnfr.200800150]

38 **Nuñez-Sánchez MA**, González-Sarrías A, García-Villalba R, Monedero-Saiz T, García-Talavera NV, Gómez-Sánchez MB, Sánchez-Álvarez C, García-Albert AM, Rodríguez-Gil FJ, Ruiz-Marín M, Pastor-Quirante FA, Martínez-Díaz F, Tomás-Barberán FA, Espín JC, García-Conesa MT. Gene expression changes in colon tissues from colorectal cancer patients following the intake of an ellagitannin-containing pomegranate extract: a randomized clinical trial. *J Nutr Biochem* 2017; **42**: 126-133 [PMID: 28183047 DOI: 10.1016/j.jnutbio.2017.01.014]

39 **Hnatyszyn A**, Hryhorowicz S, Kaczmarek-Ryś M, Lis E, Słomski R, Scott RJ, Pławski A. Colorectal carcinoma in the course of inflammatory bowel diseases. *Hered Cancer Clin Pract* 2019; **17**: 18 [PMID: 31338130 DOI: 10.1186/s13053-019-0118-4]

40 **Piwowarski JP**, Kiss AK, Granica S, Moeslinger T. Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages. *Mol Nutr Food Res* 2015; **59**: 2168-2177 [PMID: 26202092 DOI: 10.1002/mnfr.201500264]

41 **Giménez-Bastida JA**, Larrosa M, González-Sarrías A, Tomás-Barberán F, Espín JC, García-Conesa MT. Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. *J Agric Food Chem* 2012; **60**: 8866-8876 [PMID: 22463485 DOI: 10.1021/jf300290f]

42 **Larrosa M**, González-Sarrías A, Yáñez-Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, Tomás-Barberán F, Dolara P, Espín JC. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. *J Nutr Biochem* 2010; **21**: 717-725 [PMID: 19616930 DOI: 10.1016/j.jnutbio.2009.04.012]

43 **Cheah KY**, Bastian SE, Acott TM, Abimosleh SM, Lymn KA, Howarth GS. Grape seed extract reduces the severity of selected disease markers in the proximal colon of dextran sulphate sodium-induced colitis in rats. *Dig Dis Sci* 2013; **58**: 970-977 [PMID: 23143736 DOI: 10.1007/s10620-012-2464-1]

44 **Gu J**, Thomas-Ahner JM, Riedl KM, Bailey MT, Vodovotz Y, Schwartz SJ, Clinton SK. Dietary Black Raspberries Impact the Colonic Microbiome and Phytochemical Metabolites in Mice. *Mol Nutr Food Res* 2019; **63**: e1800636 [PMID: 30763455 DOI: 10.1002/mnfr.201800636]

45 **Singh R**, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang HG, Haribabu B, Vemula PK, Jala VR. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. *Nat Commun* 2019; **10**: 89 [PMID: 30626868 DOI: 10.1038/s41467-018-07859-7]

46 **Giménez-Bastida JA**, Truchado P, Larrosa M, Espín JC, Tomás-Barberán FA, Allende A, García-Conesa MT. Urolithins, ellagitannin metabolites produced by colon microbiota, inhibit Quorum Sensing in Yersinia enterocolitica: Phenotypic response and associated molecular changes. *Food Chem* 2012; **132**: 1465-1474 [PMID: 29243637 DOI: 10.1016/j.foodchem.2011.12.003]

47 **Muku GE**, Murray IA, Espín JC, Perdew GH. Urolithin A Is a Dietary Microbiota-Derived Human Aryl Hydrocarbon Receptor Antagonist. *Metabolites* 2018; **8** [PMID: 30501068 DOI: 10.3390/metabo8040086]

48 **Stewart** BW, Wild CP. International Agency for Research on Cancer, WHO. World Cancer Report 2014. Available from: https://www.who.int/cancer/publications/WRC\_2014/en/

49 **Singh S**, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 45-54 [PMID: 23938452]

50 **Wang Y**, Qiu Z, Zhou B, Liu C, Ruan J, Yan Q, Liao J, Zhu F. In vitro antiproliferative and antioxidant effects of urolithin A, the colonic metabolite of ellagic acid, on hepatocellular carcinomas HepG2 cells. *Toxicol In Vitro* 2015; **29**: 1107-1115 [PMID: 25910917 DOI: 10.1016/j.tiv.2015.04.008]

51 **Qiu Z**, Zhou J, Zhang C, Cheng Y, Hu J, Zheng G. Antiproliferative effect of urolithin A, the ellagic acid-derived colonic metabolite, on hepatocellular carcinoma HepG2.2.15 cells by targeting Lin28a/let-7a axis. *Braz J Med Biol Res* 2018; **51**: e7220 [PMID: 29742265 DOI: 10.1590/1414-431x20187220]

52 **Sharma M**, Li L, Celver J, Killian C, Kovoor A, Seeram NP. Effects of fruit ellagitannin extracts, ellagic acid, and their colonic metabolite, urolithin A, on Wnt signaling. *J Agric Food Chem* 2010; **58**: 3965-3969 [PMID: 20014760 DOI: 10.1021/jf902857v]

53 **Giles RH**, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim Biophys Acta* 2003; **1653**: 1-24 [PMID: 12781368 DOI: 10.1016/s0304-419x(03)00005-2]

54 **Zhao B**, Wang Y, Tan X, Ke K, Zheng X, Wang F, Lan S, Liao N, Cai Z, Shi Y, Zheng Y, Lai Y, Wang L, Li Q, Liu J, Huang A, Liu X. Inflammatory Micro-environment Contributes to Stemness Properties and Metastatic Potential of HCC via the NF-κB/miR-497/SALL4 Axis. *Mol Ther Oncolytics* 2019; **15**: 79-90 [PMID: 31650028 DOI: 10.1016/j.omto.2019.08.009]

55 **Olennikov DN**, Kashchenko NI, Chirikova NK. In Vitro Bioaccessibility, Human Gut Microbiota Metabolites and Hepatoprotective Potential of Chebulic Ellagitannins: A Case of Padma Hepaten® Formulation. *Nutrients* 2015; **7**: 8456-8477 [PMID: 26473917 DOI: 10.3390/nu7105406]

56 **Zhang B**, Han S, Feng B, Chu X, Chen L, Wang R. Hepatitis B virus X protein-mediated non-coding RNA aberrations in the development of human hepatocellular carcinoma. *Exp Mol Med* 2017; **49**: e293 [PMID: 28186085 DOI: 10.1038/emm.2016.177]

57 **Lamontagne J**, Steel LF, Bouchard MJ. Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. *World J Gastroenterol* 2015; **21**: 7375-7399 [PMID: 26139985 DOI: 10.3748/wjg.v21.i24.7375]

58 **Totiger TM**, Srinivasan S, Jala VR, Lamichhane P, Dosch AR, Gaidarski AA 3rd, Joshi C, Rangappa S, Castellanos J, Vemula PK, Chen X, Kwon D, Kashikar N, VanSaun M, Merchant NB, Nagathihalli NS. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. *Mol Cancer Ther* 2019; **18**: 301-311 [PMID: 30404927 DOI: 10.1158/1535-7163.MCT-18-0464]

59 **Kresty LA**, Fromkes JJ, Frankel WL, Hammond CD, Seeram NP, Baird M, Stoner GD. A phase I pilot study evaluating the beneficial effects of black raspberries in patients with Barrett's esophagus. *Oncotarget* 2018; **9**: 35356-35372 [PMID: 30450163 DOI: 10.18632/oncotarget.10457]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 31, 2020

**First decision:** April 9, 2020

**Article in press:** May 23, 2020

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Poland

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** Howarth GS, Serban ED **S- Editor:** Dou Y **L- Editor:** A **E- Editor:** Ma YJ

**Table 1 Chemopreventive activities of urolithin A against colorectal cancer**

|  |  |  |
| --- | --- | --- |
| **Cell line** | **Mechanism** | **Ref.** |
| SW620 | ↓Proliferation, MMP-9 activity | Zhao *et al*[21] |
| ↑Autophagy, LC3 |
| G2/M arrest |
| ↑Apoptosis, necrosis |
| HT-29 | ↓Proliferation | Cho *et al*[22] |
| ↑Apoptosis, necrosis |
| G2/M arrest |
| ↑p21 expression |
| ↓MMP, ↑caspase 8 and 9 activity |
| HT-29 | ↓Proliferation | Kasimsetty *et al*[23] |
| ↓G0/G1 ↑G2/M, G0 |
| ↓CYP1 activity |
| ↑Apoptosis, caspase-3 like activity |
| HT-29 | ↓Proliferation | Tortora *et al*[24] |
| Caco-2 | ↑*CYP1A*1, *UGT1A10* | González-Sarrías *et al*[25] |
| ↑CYP1A1 activity |
| 1Caco-2, HT-29, SW480 | ↓Proliferation | González-Sarrías *et al*[26] |
| S arrest (SW480, Caco-2) |
| G2/M arrest |
| Gene expression in Caco-2: |
| ↑*ABCG2, TP53, c-MYC, CDKN1A, BIRC5* |
| Gene expression in SW480: |
| ↑c*-MYC, CDKN1A, BIRC5, CASP3, EGFR* |
| ↓*CTNNB1* |
| Gene expression in HT-29: |
| ↑*CDKN1A* |
| Caco-2, HT-29, SW480 | ↓Proliferation | González-Sarrías *et al*[27] |
| G2/M (Caco-2, SW480, HT-29) |
| S (SW480, HT-29) arrest |
| HCT-116, Caco-2, HT-29 | ↓Colony formation | Giménez-Bastida *et al*[28] |
| G2/M arrest (Caco-2, HCT-116) |
| ↑Senescence-associated β–galactosidase activity (HCT-116) |
| ↑p53 and p21Cip1/Waf1 expression (HCT-116) |
| 1CSCs (Caco-2 and primary human colon tumor cells) | Caco-2: | Núñez-Sánchez *et al*[29] |
| ↓Colonosphere number |
| ↓ALDHhigh cells |
| Primary human colon tumor cells: |
| ↓Colonosphere number |
| ↓Colonosphere size |
| ↓ALDHhigh cells |
| HCT116 | ↓Cell growth | Norden *et al*[32] |
| ↑*p53, p21, TIGAR* expression |
| ↑p53, p21, TIGAR expression |
| Caco-2, HT-29, SW480 | ↓Proliferation | González-Sarrías *et al*[33] |
| ↑5-FU- and 5’-DFCR-induced cytotoxicity |
| G2/M arrest (Caco-2, SW480) |
| ↑Caspase 9 activity (Caco-2) |
| Caco-2 | NS cell vitality | Kojadinovic *et al*[36] |
| ↓ROS |
| ↓CAT activity |
| NS SOD and GPx activity |
| Caco-2 | ↓Proliferation | González-Sarrías *et al*[37] |
| Kinase signaling pathway gene expression: ↓*FGFR2*, ↑*DUSP6, c-MYC, Fos*, *CD44* |
| Human tissue samples /pomegranate extract | ↓CD44, *CTNNB1 CDKN1A, EGFR, TYMS* | Nuñez-Sánchez *et al*[29,38] |

1mixture containing urolithin A.

5-DFCR: 5-deoxy-5-fluorocytidine; 5′DFUR: 5-deoxy-5-fluorouridine; ALDH: Aldehyde dehydrogenase; CAT: Catalase; CYP450: Cytochrome P450; GPx: Glutathione peroxidase; LC3: GFP-microtubule-associated protein 1 light chain 3; MMP-9: Matrix metalloproteinase-9; NS: Non significant change; ROS: Reactive oxygen species; SOD: Superoxide dismutase; TIGAR: TP53 induced glycolysis regulatory phosphatase.

**Table 2 Anti-inflammatory activity of urolithin A relevant to the intestine**

|  |  |  |
| --- | --- | --- |
| **Cell line/model** | **Mechanism** | **Ref.** |
| CCD18-Co / cytokine-induced inflammation IL-1β or TNF-α | ↓IL-1β-induced PGE2 level | Giménez-Bastida *et al*[41] |
| ↓IL-1β or TNF-α -stimulated migration |
| ↓non-stimulated migration |
| ↓IL-1β-stimulated adhesion |
| ↑TNF-α -decreased cell viability |
| ↓IL-1β or TNF-α -induced expression of members of the EGF, PGF, PDGF, VEGF, M-CSF, and IGF families |
| ↓IL-1β -induced PAI-1 and TNF-α -induced IL-8 levels |
| Fischer rats /DSS-induced colitis | ↑HCT, RBCs | Larrosa *et al*[42] |
| ↓Loss of epithelium, total histological scores |
| ↑Bifidobacteria |
| ↓*E. coli*, enterobacteria, and total aerobic bacteria CAT activity |
| ↓NO, iNOS |
| ↓PGE2, COX-2, PTGES |
| ↑*Rb1*, *p53* ↓*CD40, IL-1β* and *IL-4* |
| C57BL/6 x FVB F1/BRB intervention | ↑Shannon diversity index | Gu *et al*[44] |
| ↑Bacteroidetes, *Barnesiella* |
| ↓Firmicutes, *Clostridium, Turicibacter, Lactobacillus* |
| BMDMs /LPS | ↓IL-6, TNF-α level | Singh *et al*[45] |
| C57BL/6 mice | ↓LPS-induced serum level of IL-6, TNF-α | Singh *et al*[45] |
| ↑Colonic and hepatic Cyp1A1 activity in WT not in AhR−/− mice |
| ↑Colonic *Cldn4, Nrf2,* and *NQO1* in WT not in AhR−/− and Nrf2−/− mice |
| ↑Colonic Cldn4, Nrf2, and NQO1 in WT not in AhR−/− and Nrf2−/− mice |
| HT-29, Caco-2 | ↑*Cldn4, Ocln,* and *ZO1* | Singh *et al*[45] |
| ↑Cldn4, Ocln, and ZO1 |
| ↓LPS-induced leakage of FITC-dextran |
| ↑*Cyp1A1*, Cyp1A1 protein expression, and activity |
| ↑AhR-reporter, nuclear translocation of AhR |
| Cldn4 expression not affected in Ahr SiRNA and CYP1A1 SiRNA cells |
| ↑Nrf2 levels, nuclear translocation of Nrf2 |
| C57BL/6 mice / TNBS | ↓Weight loss, diseases activity index, intestinal permeability | Singh *et al*[45] |
| ↓Colonic MPO level |
| ↓Serum IL-6, TNF-α, CXCL1, and IL-1β levels |
| ↑Colon length, Cldn4 |
| ↓Tissue damage and inflammation scores |
| AhR-knockdown caco-2 cells/TCDD /IL-1β /TMF | ↓*IL-6, CYP1A1, PTGS2* in siControl | Muku *et al*[47] |
| NS *IL-6, CYP1A1, PTGS2* in siAhR |

AhR: Aryl hydrocarbon receptor; BMDMs: Mouse bone marrow derived macrophages, BRB: Black raspberries; CAT: Catalase; Cldn4: Claudin 4; COX-2: Cyclooxygenase 2; CXCL1: Chemokine (C-X-C motif) ligand 1; CYP: Cytochrome; EGF: Epidermal growth factor; HCT: Haematocrit; IGF: Insulin-like growth factor; IL: Interleukin; iNOS: Inducible nitric oxide synthase; LPS: Lipopolysaccharide; M-CSF: Macrophage colony-stimulating factor; MPO: Myeloperoxidase; ns: non significant change; NO: Nitric oxide; Nrf2: Nuclear factor erythroid 2-related factor 2 ; NQO1: NAD(P)H dehydrogenase [quinone] 1; Ocln: Occludin; siAhR: AhR knockdown by siRNA Caco-2 cells; siControl: Caco-2 cells transfected with siControl; PAI-1: Plasminogen activator inhibitor-1; PDGF: Platelet-derived growth factor; PGE2: Prostaglandin E2; PTGES: Prostaglandin E synthase; PGF: Placental growth factor; PTGS2: Prostaglandin-endoperoxide synthase; RBCs: Red blood cells; TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin (agonist of AhR); TMF: 6,2',4'-trimethoxyflavone (AhR antagonist); TNBS: 2,4,6-Trinitrobenzenesulfonic acid; TNF-α: Tumor necrosis factor α; WT: Wild type; VEGF: Vascular endothelial growth factor; ZO-1: Zonula occludens-1.

**Table 3 Chemopreventive activities of urolithin A against other cancers of the alimentary tract**

|  |  |  |
| --- | --- | --- |
| **Cell line/model** | **Mechanism** | **Ref.** |
| Liver | | |
| HepG2 | ↓Cell survival | Wang *et al*[50] |
| ↓Wnt/β-catenin signalling; *β-catenin* |
| ↓*c-MYc, cyclin D1, phospo-c-Jun* |
| ↓*IL-6, IL-1β, NF-κβ, Cox-2, iNOS* |
| ↑*TP53, BAX, PUMA, NOXA, p53, phosphor-p53* |
| ↑*Caspase-3, phospho-p38* |
| ↓H2O2-induced ROS, MDA level |
| ↑SOD level, GPx activity in H2O2-induced oxidative stress |
| HepG2.2.15 | ↓Cell proliferation | Qiu *et al*[51] |
| ↓Bcl-2 |
| ↑Cleaved caspase-3, Bax |
| ↓Lin28a, Zcchc11, Sp-1 |
| ↑Let-7a |
| ↓HMGA2, K-ras |
| ↓Invasive cell number |
| Cultured rat hepatocytes/*t*-BHT | ↓Cytotoxicity | Olennikov *et al*[55] |
| ↓LDH, MDA level |
| Pancreas | | |
| The human PDAC cell lines (MiaPaCa2, PANC1, AsPC1, CFPAC1, Capan1, Capan2, SW1990, HPAC, BxPC3) | ↓Cell proliferation, migration, apoptosis | Totiger *et al*[58] |
| ↓pAKT (T308), p70S6K (T421/S424), PDK1, pGSK3β, p4E-BP1 |
| PDAC xenografts in mice | ↓Tumor volume | Totiger *et al*[58] |
| ↓pAKT (T308), p70S6K (T421/S424)  ↓Ki67 |
| ↑Cleaved caspase-3 |
| PKT mice | ↓Tumor weight | Totiger *et al*[58] |
| ↑Survival  ↓pAKT (T308), p70S6K (T421/S424) |
| ↓Ki67 |
| ↑Cleaved caspase-3 |
| ↓F4/80-, Fox-P3, CD3- positive cells |
| Esophagus | | |
| BE patients/LBR intervention | ↑GST-pi level in BE biopsies | Kresty *et al*[59] |

BE: Barrett’s esophagus; Bcl-2: B-cell lymphoma 2; GST: Glutathione S-transferase; HMG2: High-mobility group AT-hook 2, MDA: Malondialdehyde; *t*-BHP: *tert*-butyl hydroperoxide; LBR: Lyophilized black raspberries; LDH: Lactate dehydrogenase; MMP: Matrix metalloproteinase; PDAC: Pancreatic ductal adenocarcinoma; ROS: Reactive oxygen species; SOD: Superoxide dismutase; HMGA2: High mobility group AT-hook 2.